Clinical Trial of the Week: Treatment trial for patients diagnosed certain types of breast cancer

By Donna Loyle, communications specialist, LIMR

Researchers seek patients diagnosed with node-positive or high-risk node negative triple negative invasive breast cancer for a randomized phase III treatment trial. There are two treatment arms. All study participants receive the medications doxorubicin hydrochloride, cyclophosphamide and paclitaxel. Those in Arm 2 also receive carboplatin.

Study #BR003 is available at all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. More information is available at:

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *